Since EYO is not available in sporadic Alzheimer’s disease subjects, we used CSF total tau levels as a marker of disease severity that is closely linked to neurodegeneration and memory decline (Brier et al., 2016). This evidence concerns the gene MAPT and Alzheimer disease.